These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

192 related articles for article (PubMed ID: 31102467)

  • 21. Drug and bile acid transporters in rosuvastatin hepatic uptake: function, expression, and pharmacogenetics.
    Ho RH; Tirona RG; Leake BF; Glaeser H; Lee W; Lemke CJ; Wang Y; Kim RB
    Gastroenterology; 2006 May; 130(6):1793-806. PubMed ID: 16697742
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The impact of solute carrier (SLC) drug uptake transporter loss in human and rat cryopreserved hepatocytes on clearance predictions.
    Lundquist P; Lööf J; Sohlenius-Sternbeck AK; Floby E; Johansson J; Bylund J; Hoogstraate J; Afzelius L; Andersson TB
    Drug Metab Dispos; 2014 Mar; 42(3):469-80. PubMed ID: 24396146
    [TBL] [Abstract][Full Text] [Related]  

  • 23. PET imaging-based evaluation of hepatobiliary transport in humans with (15R)-11C-TIC-Me.
    Takashima T; Kitamura S; Wada Y; Tanaka M; Shigihara Y; Ishii H; Ijuin R; Shiomi S; Nakae T; Watanabe Y; Cui Y; Doi H; Suzuki M; Maeda K; Kusuhara H; Sugiyama Y; Watanabe Y
    J Nucl Med; 2012 May; 53(5):741-8. PubMed ID: 22499612
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Successful Prediction of Human Hepatic Concentrations of Transported Drugs Using the Proteomics-Informed Relative Expression Factor Approach.
    Yin M; Balhara A; Marie S; Tournier N; Gáborik Z; Unadkat JD
    Clin Pharmacol Ther; 2024 Mar; 115(3):595-605. PubMed ID: 38037845
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Hepatic transport mechanisms of cholyl-L-lysyl-fluorescein.
    de Waart DR; Häusler S; Vlaming ML; Kunne C; Hänggi E; Gruss HJ; Oude Elferink RP; Stieger B
    J Pharmacol Exp Ther; 2010 Jul; 334(1):78-86. PubMed ID: 20388726
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Evaluation of the endothelin receptor antagonists ambrisentan, darusentan, bosentan, and sitaxsentan as substrates and inhibitors of hepatobiliary transporters in sandwich-cultured human hepatocytes.
    Hartman JC; Brouwer K; Mandagere A; Melvin L; Gorczynski R
    Can J Physiol Pharmacol; 2010 Jun; 88(6):682-91. PubMed ID: 20628435
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Interaction of fluvastatin with the liver-specific Na+ -dependent taurocholate cotransporting polypeptide (NTCP).
    Greupink R; Dillen L; Monshouwer M; Huisman MT; Russel FG
    Eur J Pharm Sci; 2011 Nov; 44(4):487-96. PubMed ID: 21945488
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Prediction and Quantification of Hepatic Transporter-Mediated Uptake of Pitavastatin Utilizing a Combination of the Relative Activity Factor Approach and Mechanistic Modeling.
    Mitra P; Weinheimer S; Michalewicz M; Taub ME
    Drug Metab Dispos; 2018 Jul; 46(7):953-963. PubMed ID: 29666154
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Involvement of multiple transporters in the hepatobiliary transport of rosuvastatin.
    Kitamura S; Maeda K; Wang Y; Sugiyama Y
    Drug Metab Dispos; 2008 Oct; 36(10):2014-23. PubMed ID: 18617601
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Development of a mechanistic biokinetic model for hepatic bile acid handling to predict possible cholestatic effects of drugs.
    Notenboom S; Weigand KM; Proost JH; van Lipzig MMH; van de Steeg E; van den Broek PHH; Greupink R; Russel FGM; Groothuis GMM
    Eur J Pharm Sci; 2018 Mar; 115():175-184. PubMed ID: 29309877
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Electrophysiological characterization of human Na⁺/taurocholate cotransporting polypeptide (hNTCP) heterologously expressed in Xenopus laevis oocytes.
    Masuda M; Ichikawa Y; Shimono K; Shimizu M; Tanaka Y; Nara T; Miyauchi S
    Arch Biochem Biophys; 2014 Nov; 562():115-21. PubMed ID: 25168282
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Toward improved predictions of pharmacokinetics of transported drugs in hepatic impairment: Insights from the extended clearance model.
    Storelli F; Ladumor MK; Liang X; Lai Y; Chothe PP; Enogieru OJ; Evers R; Unadkat JD
    CPT Pharmacometrics Syst Pharmacol; 2024 Jan; 13(1):118-131. PubMed ID: 37833845
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Organic Anion-Transporting Polypeptide and Efflux Transporter-Mediated Hepatic Uptake and Biliary Excretion of Cilostazol and Its Metabolites in Rats and Humans.
    Wang C; Huo X; Wang C; Meng Q; Liu Z; Sun P; Cang J; Sun H; Liu K
    J Pharm Sci; 2017 Sep; 106(9):2515-2523. PubMed ID: 28535976
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Role of transporters in hepatic drug disposition].
    Gao CY; Chen XY; Zhong DF
    Yao Xue Xue Bao; 2012 May; 47(5):565-72. PubMed ID: 22811997
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The hepatobiliary disposition of timosaponin b2 is highly dependent on influx/efflux transporters but not metabolism.
    Sheng J; Tian X; Xu G; Wu Z; Chen C; Wang L; Pan L; Huang C; Pan G
    Drug Metab Dispos; 2015 Jan; 43(1):63-72. PubMed ID: 25336752
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Cyclosporin A inhibits hepatitis B and hepatitis D virus entry by cyclophilin-independent interference with the NTCP receptor.
    Nkongolo S; Ni Y; Lempp FA; Kaufman C; Lindner T; Esser-Nobis K; Lohmann V; Mier W; Mehrle S; Urban S
    J Hepatol; 2014 Apr; 60(4):723-31. PubMed ID: 24295872
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Fasiglifam (TAK-875) Inhibits Hepatobiliary Transporters: A Possible Factor Contributing to Fasiglifam-Induced Liver Injury.
    Li X; Zhong K; Guo Z; Zhong D; Chen X
    Drug Metab Dispos; 2015 Nov; 43(11):1751-9. PubMed ID: 26276582
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Regulation of human hepatic drug transporter activity and expression by diesel exhaust particle extract.
    Le Vee M; Jouan E; Stieger B; Lecureur V; Fardel O
    PLoS One; 2015; 10(3):e0121232. PubMed ID: 25803276
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Regulation of hepatic drug transporter activity and expression by organochlorine pesticides.
    Bucher S; Le Vee M; Jouan E; Fardel O
    J Biochem Mol Toxicol; 2014 Mar; 28(3):119-28. PubMed ID: 24464585
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Transport Kinetics, Selective Inhibition, and Successful Prediction of In Vivo Inhibition of Rat Hepatic Organic Anion Transporting Polypeptides.
    Ishida K; Ullah M; Tóth B; Juhasz V; Unadkat JD
    Drug Metab Dispos; 2018 Sep; 46(9):1251-1258. PubMed ID: 29891589
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.